BeOne Medicines

SHH:688235 · CNE100005XT6

BiotechnologyX-Large

360

Value52

Profit price14

EV / EBIT21

Price / Owner Earnings7

Cash yield33

Owner Earnings Yield65

Dividend Yield1

Sales & asset price59

Price/Sales59

EV / Gross Profit94

Price/Book24

Quality69

Returns on capital73

Return on Capital76

Cash Return on Capital71

Return on Equity71

Profit margins70

EBIT Margin48

Gross Profitability92

Cash backing66

Cash Conversion86

Accruals56

Owner Earnings Margin55

Growth53

Sales growth58

Profit growth94

Reinvestment54

Price momentum47

Safety59

Debt load55

Debt serviceability78

Refinancing56

Debt Payback100

Liquidity82

Sentiment63

Analyst ratings64

Expectations trend84

Opinion Changes81

Price Target Upside86

Market mood3

Value Creation20/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

BeOne Medicines generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySwitzerland

IndustryBiotechnology

SizeX-Large

TypePublic Company

ExchangeNASDAQGS

Founded2010

Employees1,904

Websitebeonemedicines.com

ISINCNE100005XT6

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Stem Cell TherapyImmunologyHematologyHealth DiagnosticsGastroenterologyOncologyBiotechnologyHealth CareLife ScienceMedical

Description

BeOne Medicines AG operates as a global oncology company discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. The company is a serial innovator in hematology and has built a different…

Analysis

Quality compounder

BeOne Medicines AG earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 59.8×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is adequate. The company scores 20/20 on our value-creation score: strong value creator. Analysts lean positive.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare BeOne Medicines with its peers

Newron Pharmaceuticals

SWX:NWRN

CountryItaly

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Roivant Sciences

NSQ:ROIV

CountryUK

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Molecular Partners

SWX:MOLN

CountrySwitzerland

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Prothena Corporation

NSQ:PRTA

CountryIreland

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Kiniksa Pharmaceuticals

NSQ:KNSA

CountryUK

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Alvotech

NMQ:ALVO

CountryLuxembourg

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →